Morgan Stanley Initiates Q32 Bio at Overweight with $34 Target — 113% Upside Potential

Morgan Stanley initiates Q32 Bio at Overweight ($34 target) as bempikibart matches JAK efficacy in alopecia areata while offering cleaner safety, less monitoring and durability.